Brokerages Set 4D Molecular Therapeutics, Inc. (NASDAQ:FDMT) PT at $30.40

4D Molecular Therapeutics, Inc. (NASDAQ:FDMT - Get Free Report) has received an average recommendation of "Moderate Buy" from the eleven research firms that are covering the stock, Marketbeat Ratings reports. One equities research analyst has rated the stock with a sell rating, two have assigned a hold rating and eight have assigned a buy rating to the company. The average 1 year price target among brokers that have updated their coverage on the stock in the last year is $30.40.

Several brokerages recently issued reports on FDMT. Chardan Capital restated a "buy" rating and issued a $25.00 price target on shares of 4D Molecular Therapeutics in a research report on Tuesday, August 12th. Weiss Ratings restated a "sell (d-)" rating on shares of 4D Molecular Therapeutics in a research report on Saturday, August 30th. Finally, Roth Capital dropped their price target on 4D Molecular Therapeutics from $44.00 to $38.00 and set a "buy" rating on the stock in a research report on Tuesday, August 12th.

4D Molecular Therapeutics Price Performance

Shares of FDMT traded up $0.14 during midday trading on Monday, reaching $7.08. 365,049 shares of the stock were exchanged, compared to its average volume of 854,869. The business's 50-day moving average price is $5.58 and its 200 day moving average price is $4.32. 4D Molecular Therapeutics has a twelve month low of $2.23 and a twelve month high of $17.41. The company has a market capitalization of $330.50 million, a price-to-earnings ratio of -2.01 and a beta of 2.86.

4D Molecular Therapeutics (NASDAQ:FDMT - Get Free Report) last posted its earnings results on Monday, August 11th. The company reported ($0.98) EPS for the quarter, missing analysts' consensus estimates of ($0.88) by ($0.10). 4D Molecular Therapeutics had a negative return on equity of 40.15% and a negative net margin of 594,375.81%.The firm had revenue of $0.01 million for the quarter, compared to analyst estimates of $0.52 million. As a group, equities research analysts expect that 4D Molecular Therapeutics will post -2.84 earnings per share for the current fiscal year.

Hedge Funds Weigh In On 4D Molecular Therapeutics

Several institutional investors have recently added to or reduced their stakes in FDMT. BVF Inc. IL increased its position in 4D Molecular Therapeutics by 70.8% in the 1st quarter. BVF Inc. IL now owns 4,561,289 shares of the company's stock valued at $14,733,000 after acquiring an additional 1,890,647 shares during the period. Millennium Management LLC boosted its holdings in 4D Molecular Therapeutics by 1,607.1% in the 4th quarter. Millennium Management LLC now owns 1,420,723 shares of the company's stock valued at $7,913,000 after purchasing an additional 1,337,497 shares in the last quarter. Federated Hermes Inc. raised its stake in shares of 4D Molecular Therapeutics by 33,131.8% during the 1st quarter. Federated Hermes Inc. now owns 1,250,181 shares of the company's stock worth $4,038,000 after buying an additional 1,246,419 shares in the last quarter. Cubist Systematic Strategies LLC raised its stake in shares of 4D Molecular Therapeutics by 2,084.5% during the 4th quarter. Cubist Systematic Strategies LLC now owns 448,831 shares of the company's stock worth $2,500,000 after buying an additional 428,285 shares in the last quarter. Finally, Acadian Asset Management LLC raised its stake in shares of 4D Molecular Therapeutics by 1,103.4% during the 1st quarter. Acadian Asset Management LLC now owns 400,606 shares of the company's stock worth $1,290,000 after buying an additional 367,317 shares in the last quarter. Institutional investors and hedge funds own 99.27% of the company's stock.

About 4D Molecular Therapeutics

4D Molecular Therapeutics, Inc, a clinical-stage biotherapeutics company, develops genetic medicines using its therapeutic vector evolution platform in the Netherland and the United States. The company develops a portfolio of genetic medicine product candidates focuses in three therapeutic areas for ophthalmology, cardiology, and pulmonology.